Canadian Cardiovascular Society Position Statement on POTS and Related Disorders of Chronic Orthostatic Intolerance

Authors, Journal, Affiliations, Type, DOI

• Authors: Satish R. Raj (Chair), Juan C. Guzman (Co-chair), Paula Harvey, Lawrence Richer, Ronald Schondorf, Colette Seifer, Nicolas Thibodeau-Jarry, Robert S. Sheldon
• Journal: Canadian Journal of Cardiology, Vol 36, 2020, pp. 357–372
• Affiliations: University of Calgary (Libin Cardiovascular Institute), McMaster University, University of Toronto, University of Alberta, McGill University (Jewish General Hospital), University of Manitoba, Université de Montréal
• Type: National society position statement; systematic review with GRADE recommendations
• DOI: https://doi.org/10.1016/j.cjca.2019.12.024

Overview

This 2020 CCS position statement by Raj and colleagues provides a comprehensive update to POTS diagnosis and management using GRADE methodology. Its most original contribution is a novel nomenclature ecosystem for chronic orthostatic intolerance that extends beyond traditional POTS — introducing POTS plus, postural symptoms without tachycardia (PSWT), PSWT plus, and postural tachycardia of other cause (PTOC) — directly addressing a recognised widespread pattern of POTS misdiagnosis in clinical practice. The statement also provides greater diagnostic precision (minimum standing HR thresholds, sustained criteria), a stepwise treatment algorithm anchored by strong-evidence non-pharmacological strategies, and explicit strong recommendations against several procedural interventions (sinus node RF ablation, Chiari decompression, jugular venoplasty) that had entered practice without adequate evidence.

Keywords

Postural orthostatic tachycardia syndrome, orthostatic intolerance, POTS plus, PSWT, PTOC, autonomic dysfunction, midodrine, propranolol, ivabradine, exercise training, nomenclature, GRADE

Key Takeaways

Definitions and Diagnostic Criteria — New Nomenclature Ecosystem

POTS (unchanged core criteria, with CCS clarifications)

• Heart rate increase ≥30 bpm (adults >19 yr) or ≥40 bpm (ages 12–19 yr) from supine to upright within 10 minutes, sustained on ≥2 recordings at least 1 minute apart
• Absence of orthostatic hypotension (systolic BP drop >20 mmHg or diastolic >10 mmHg within 3 minutes of standing); transient initial orthostatic hypotension lasting <1 minute does NOT preclude POTS diagnosis
• Minimum upright HR threshold: Adults must reach ≥90 bpm (teens ≥100 bpm); if supine resting HR <60 bpm, 60 bpm is used as the reference (not actual resting HR)
• The CCS does NOT include "HR >120 bpm without orthostatic tachycardia" as a stand-alone criterion (excluded from CCS POTS criteria, fits better as IST)
• Criteria do not need to be met at every visit — POTS status should not change visit-to-visit if HR increase briefly falls below threshold
• Duration: symptoms and hemodynamics must be chronic, persisting ≥3 months
• POTS is a heterogeneous syndrome, not a specific disease; it is expected that discrete subtypes will be identified over time

POTS Plus

• Meets all POTS criteria PLUS one or more debilitating non-cardiovascular symptoms: gastric emptying problems, intractable vomiting, severe constipation, neurogenic bladder, severe chronic pain, intractable headaches, significant flushing/anaphylaxis symptoms, severe food intolerances
• May have associated comorbid diagnoses: hypermobile EDS (25%), CFS/ME (21%), fibromyalgia (20%), autoimmune disorder (16%), MCAS (9%), celiac disease (3%), chronic migraines/CSF leak, mitochondrial disorders, multiple sclerosis

PSWT (Postural Symptoms Without Tachycardia)

• Meets POTS symptom criteria but does NOT meet hemodynamic criteria
• Should NOT be diagnosed as POTS, even though treatment approaches may overlap
• A patient may initially meet PSWT criteria and later qualify for POTS if hemodynamics are documented on repeat testing

PSWT Plus

• PSWT criteria + debilitating non-cardiovascular symptoms (same as POTS plus)
• May have same comorbid conditions as POTS plus

PTOC (Postural Tachycardia of Other Cause)

• Meets hemodynamic criteria for POTS but has a clear secondary underlying cause that precludes the POTS diagnosis
• Causes: acute hypovolemia, endocrinopathy (carcinoid, adrenal insufficiency, Cushing, hyperthyroidism, phaeochromocytoma), anaemia, anxiety/panic attacks, medication side effects, recreational drug effects, prolonged bedrest
• Expected to resolve with treatment of the underlying cause
• Should NOT be diagnosed as POTS

Asymptomatic Orthostatic Tachycardia

• Meets hemodynamic criteria but asymptomatic or minimally symptomatic
• Should NOT be diagnosed as POTS; usually does not require specific treatment (reassurance only)
• Increasingly detected by wearable HR monitors

IST (for context)

• Resting sinus HR >100 bpm (mean 24h HR >90 bpm) not due to primary cause, associated with distressing palpitations
• Distinct hemodynamic pattern from POTS; shares many symptoms

Epidemiology and Natural History

• Prevalence in Canada unknown; US data suggest 0.1–1.0% of general population
• Onset typically age 13–40 years; >90% female
• Without adequate treatment, POTS can be debilitating with impaired quality of life; mortality rarely directly attributable to POTS
• Prognosis variable; many patients improve with appropriate treatment
• Pediatric prevalence estimated at ~1%; median onset age 13 years

Pathophysiology — Four Subtypes

• Mechanisms often coexist within individual patients
• Strong Recommendation (Low-Quality Evidence): Do NOT routinely subtype during initial diagnosis due to lack of validated tools

Diagnosis and Evaluation

Recommended Initial Assessment

• Complete clinical history: triggers/precipitants (infection in up to 50%, surgery, pregnancy); symptom severity/QoL; diet (salt/water); exercise capacity; autonomic review of systems (sudomotor, secretomotor, cardiovascular, GI, genitourinary); medication history (stimulants, α-blockers, β-blockers, CCB, SNRI, MAOi, TCA, phenothiazine all can worsen POTS)
• Physical examination: orthostatic vital signs (supine ≥5 minutes then upright up to 10 minutes); complete cardiac and neurological examination
• 12-lead ECG
• Routine bloods: CBC, electrolytes (Na⁺, K⁺, Cl⁻), creatinine, urea, ferritin, TSH, morning cortisol

Orthostatic Vital Sign Protocol (GRADE: Strong, Moderate QOE)

• Supine for ≥5 minutes, then stand for up to 10 minutes
• Orthostatic tachycardia must be sustained (≥2 consecutive recordings ≥1 minute apart, after the first minute)
• Can use intermittent automated/manual brachial cuff ± continuous noninvasive HR monitoring (ECG, PPG sensors, smart watches, fitness monitors)

Against Routine Ancillary Testing (GRADE: Strong, Moderate QOE)

• Echocardiogram, external ECG loop monitoring: not routine; consider only for structural heart disease or arrhythmia not from sinus node concern
• Tilt table test, autonomic testing, plasma catecholamines, autoimmune workup, blood volume assessment, neuroimaging: not routine (Weak Recommendation, Low QOE)
• Neuroimaging/neurological studies: only for clear focal neurological deficits
• Additional testing in selected patients for diagnostic clarification or targeted therapy: Strong Recommendation, Moderate QOE

Comorbidity Screening (GRADE: Strong, Moderate QOE)

• Screen for underlying/comorbid conditions causing POTS plus — alters treatment response and prognosis

Treatment and Management

Multidisciplinary Approach (Weak Recommendation, Low QOE)

• Team including physicians, physiotherapist, exercise physiologist, kinesiologist, occupational therapist, dietician, psychologist/social worker

Non-Pharmacological (First-Line for All)

Withdraw aggravating medications (Strong Recommendation, Low QOE)

• Remove stimulants, α-blockers, excessive β-blockers, CCB, SNRI, MAOi, TCA, phenothiazine where possible

Salt and fluid loading (Strong Recommendation, Low-to-Moderate QOE)

• Daily oral fluid: ≥3 L/day
• Daily oral NaCl: 10 g/day via high-salt foods, NaCl sachets, salt sticks, or salt tablets
• If suboptimal salt intake suspected, measure 24h urinary sodium (target >170 mmol/day)
• Sleep in head-up tilt position (>10°) to promote volume expansion and reduce nocturnal diuresis

Lower body compression garments (Weak Recommendation, Low QOE)

• Waist-high compression stockings or abdominal binders to reduce venous pooling
• Start 20–30 mmHg; increase to 30–40 mmHg as tolerated
• Compression below the thighs alone is unlikely to be effective
• Educate on counter-pressure manoeuvres; avoid warm environments and prolonged standing

Exercise training (Strong Recommendation, Moderate QOE)

• Core of all treatment strategies; may achieve remission in a proportion
• Aerobic training with leg resistance training
• ≥4 sessions/week; ≥30 minutes/session; initially semirecumbent (rowing, recumbent cycle, swimming)
• 4–6 weeks before improvement is noticed
• Upright exercise poorly tolerated initially; structured programs with trainer or cardiac rehab may help

Pharmacological Management

Midodrine practical notes: Prodrug → short-acting peripheral α-1 agonist; give before upright activities; do not give supine (supine hypertension risk); "pill in pocket" approach for acute symptoms; most benefit in hypotensive/low BP phenotype; less benefit in hyperadrenergic patients with hypertension tendency

Propranolol practical notes: Non-selective preferred over cardioselective (β1-selective); higher doses and long-acting formulations do NOT improve symptoms; may worsen exercise tolerance and fatigue — problematic when exercise program concurrent

Pyridostigmine practical notes: Peripheral AChE inhibitor; combine with β-blocker if needed; diarrhea common — poorly tolerated in frequent bowel actions but beneficial in constipation-predominant patients; may worsen bladder dysfunction

Fludrocortisone practical notes: Useful if unable to optimise oral salt intake; monitor electrolytes (especially K⁺); avoid in migraine history (can worsen frequency); risk of oedema, hypokalaemia, possible osteoporosis in young women

Ivabradine practical notes: Alternative to β-blocker particularly when fatigue, asthma, or hypotension tendency; teratogenic — adequate contraception required; availability in Canada may be limited (off-label)

Clonidine/methyldopa practical notes: Central sympatholytic agents; for prominent hyperadrenergic symptoms (palpitations, tremors, orthostatic hypertension); avoid in relative supine hypotension; side effects include sedation, dry mouth

IV saline notes: Occasional rescue for acute decompensation; bridging therapy during exercise program initiation; chronic routine use not recommended (central access complications: infection, thrombosis)

Procedural Strategies — All Not Recommended

Special Considerations

Pediatric (ages 12–19)

• POTS prevalence ~1%; median onset age 13 years; associated comorbidities (CFS, sleep disturbances, dizziness, syncope, migraines, functional GI disorders, fibromyalgia, joint hypermobility) equally prevalent
• Diagnostic threshold: HR increase ≥40 bpm + standing HR ≥100 bpm (Strong Recommendation, Moderate QOE)
• Normal adolescents can achieve larger orthostatic HR increases than adults
• Non-pharmacological treatment first (same as adults); exercise programs must account for motor development, safety, equipment access; home-based preferred
• Pharmacological treatment (midodrine, fludrocortisone, β-blockers, ivabradine) if non-pharmacological inadequate (Weak Recommendation, Very Low QOE)
• Assess school performance/attendance as marker of treatment response (Strong Recommendation, Low QOE)
• Two small RCTs of midodrine in pediatric POTS — both showed significant benefit on orthostatic tolerance

When to Refer to Specialist

• Primary care physicians should manage initial diagnosis, exclusion of alternatives, and first-line treatments (Strong Recommendation, Very Low QOE)
• Refer for: diagnostic uncertainty, poor response to non-pharmacological and initial pharmacological treatments (Strong Recommendation, Very Low QOE)

Limitations of the Document

• No medium-term or long-term pharmacological RCTs in POTS; most drug evidence from acute crossover trials or retrospective series
• No pharmacological therapies are currently approved for POTS in Canada
• POTS plus and related nomenclature (PSWT, PTOC) are based on expert opinion; require prospective validation
• Prevalence in Canada unknown; estimates derived from US data
• Pathophysiological subtyping tools lack clinical validation — subtyping not recommended routinely
• Pediatric evidence largely extrapolated from adult studies

Key Concepts Mentioned

• concepts/POTS — comprehensive update to diagnostic criteria; new nomenclature ecosystem; stepwise treatment
• concepts/Inappropriate-Sinus-Tachycardia — IST defined for contrast with POTS; distinct hemodynamic pattern

Key Entities Mentioned

• Midodrine — first-line α-1 agonist; Strong Recommendation, Moderate QOE
• Propranolol — first-line non-selective β-blocker at low dose; Strong Recommendation, Moderate QOE
• Pyridostigmine — peripheral AChE inhibitor; Weak Recommendation
• Fludrocortisone — mineralocorticoid volume expansion; Weak Recommendation
• Ivabradine — If current blocker; Weak Recommendation
• Ehlers-Danlos syndrome (hypermobile type) — most prevalent comorbidity in POTS plus (25%)

Wiki Pages Updated

• Created wiki/sources/pots-ccs-2020.md
• Updated wiki/concepts/POTS.md — added CCS nomenclature ecosystem, diagnostic clarifications, updated treatment hierarchy with GRADE strengths
• Updated wiki/sourceindex.md
• Updated wiki/wikiindex.md
• Appended log.md